Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, efficacy, tolerability, and systemic pharmacokinetics of
3 different doses of topical ophthalmic AGN-223575 suspension compared to AGN-223575 vehicle
in patients with dry eye disease.